Financials
| 2025 Interim Results | Aug. 07, 2025 |
| 2024 Final Results and Business Updates | Mar. 19, 2025 |
| 2024 Interim Results and Business Updates | Jul. 31, 2024 |
| 2023 Full Year Results and Business Updates | Feb. 28, 2024 |
| Interim Results and Business Updates | Jul. 31, 2023 |
| 2022 Full Year Results and Business Updates | Feb. 28, 2023 |
| Interim Results and Business Updates | Aug. 01, 2022 |
Proxies
| 2024 Annual Report and Notice of AGM | Apr. 07, 2025 |
| Result of AGM | May. 10, 2024 |
| 2023 Annual Report and Notice of AGM | Apr. 08, 2024 |
| Annual General Meeting Poll Results | May. 12, 2023 |
| 2022 Annual Report and Notice of AGM | Apr. 11, 2023 |
| Annual General Meeting Poll Results | Apr. 27, 2022 |
| 2021 Annual Report and Notice of AGM | Mar. 23, 2022 |
Ownership Update
| Vesting of awards under Long Term Incentive Plan | Oct. 21, 2025 |
| Grant of Share Options and Awards under LTIP | Jun. 10, 2025 |
| Vesting of awards under Long Term Incentive Plan | Mar. 14, 2025 |
| Vesting of awards under the LTIP | Oct. 21, 2024 |
| Standard form for notification of major holdings | Aug. 22, 2024 |
| LTIP and Share Option Scheme | Aug. 06, 2024 |
| Vesting of Awards Under the LTIP | Apr. 22, 2024 |
Announcements
| HUTCHMED to Announce 2025 Final Results | Feb. 06, 2026 |
| Publication of Phase III Results in The Lancet | Jan. 14, 2026 |
| Surufatinib + Camrelizumab PDAC Phase 3 initiation | Jan. 05, 2026 |
| Total Voting Rights | Dec. 31, 2025 |
| China NDA Acceptance-Savolitinib in Gastric Cancer | Dec. 30, 2025 |
| NDA Acceptance in China for Fanregratinib | Dec. 29, 2025 |
| Blocklisting Six Monthly Return | Dec. 29, 2025 |